C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis  by Krieger, Elisabeth et al.
C-reactive protein and red cell aggregation
correlate with late venous function after acute
deep venous thrombosis
Elisabeth Krieger, MD,a Bernd van Der Loo, MD,a Beatrice R. Amann-Vesti, MD,a
Valentin Rousson, PhD,b and Renate Koppensteiner, MD,a Zurich, Switzerland
Objective: Risk factors leading to development and subsequent progression of chronic venous insufficiency after acute deep
venous thrombosis (DVT) are only partially identified. Inflammation and rheologic abnormalities might have a causative
role. The purpose of this study was to investigate C-reactive protein (CRP), D-dimer, and blood rheologic parameters in
patients after acute DVT in relation to clinical outcome.
Subjects and Methods: Patients with a history of acute proved DVT underwent clinical examination and duplex ultrasound
scanning of the veins, and Venous Clinical Severity Score (VCSS) and Venous Segmental Disease Score (VSDS) were
calculated. Further, CRP, D-dimer, and several rheologic parameters were determined and related to outcome as assessed
with venous scores.
Results: Forty-three patients were examined 28 (median) months after the index event. Patients had higher CRP (P < .001),
D-dimer (P < .001), red blood cell aggregation (P < .01), fibrinogen concentration (P < .01), and leukocyte count (P < .05)
than did healthy control subjects. CRP and red blood cell aggregation were positively correlated with VCSS (r 0.42 and P
< .01, and r 0.30 and P < 0.05, respectively). Multivariate regression analysis showed that the relation between CRP and
VCSS was independent of other laboratory and rheologic parameters and of age, total thrombus load, duration of compression
therapy after the index event, recurrence, recanalization, and presence of comorbid conditions (P < .05).
Conclusions: CRP is independently related to the severity of venous dysfunction in patients after acute DVT. Chronic
inflammation as well as changes in blood rheologic parameters may be causally involved in the development of chronic
venous insufficiency occurring in the medium-term and long-term course after acute DVT. (J Vasc Surg 2004;40:
644-9.)After acute deep venous thrombosis (DVT) patients are
at increased risk for development of chronic venous insuf-
ficiency (CVI) due to post-thrombotic syndrome. Factors
that contribute to development and progression of the
disease include chronic venous hypertension, ultimately
leading to disturbances in the microcirculation (eg, capil-
lary damage) and changes in blood viscosity.1
A low incidence of post-thrombotic syndrome, as a
result of administration of oral anticoagulant agents and
regular compression therapy, has been demonstrated in
patients at low risk in a long-term follow-up study after
DVT (Zurich study).2 In this study only 5% of patients
developed marked trophic changes. However, the rate of
recurrence was 24%. Several clinical, acquired, and inher-
ited risk factors for development of post-thrombotic syn-
drome, such as the initial extent of thrombus (total throm-
bus load),3 ipsilateral recurrent DVT,4 and thrombophilia-
associated genetic disorders including activated protein C
resistance caused by factor V Leiden mutation,5 have been
identified. Furthermore, both increased serologic markers
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doi:10.1016/j.jvs.2004.07.004644of activated coagulation, such as prothrombin fragments 1
and 2 and markers of inhibited fibrinolysis, such as antigen
levels against tissue plasminogen activator, after acute DVT
are inversely related to the extent of recanalization.6 Red
blood cell aggregability, another crucial determinant of
blood viscosity, also is increased in patients with a history of
unexplained DVT, which suggests a causal relationship
between alterations in blood rheologic parameters and
thromboembolic events.7
There is increasing clinical and experimental evidence
that inflammatory processes, in combination with alter-
ations in blood rheologic parameters, might also have a
pivotal role in the setting of acute DVT. In a recent study
plasma C-reactive protein (CRP) was significantly increased
in patients with acute DVT,8 which suggests a role for an
inflammatory component in the pathogenesis of CVI after
DVT. In another study, increased expression of vascular cell
adhesion molecule-1, a ligand expressed by cytokine-
stimulated endothelium, was significantly linked to the
occurrence of venous thromboembolism.9
However, to date, markers of inflammation have not
yet been thoroughly investigated in patients after DVT in
relation to their clinical mid-term to long-term outcome.
Therefore the purpose of our study was to investigate
CRP, D-dimer, and rheologic parameters in patients after
acute DVT. Furthermore, we wanted to examine in partic-
ular the relationship of these parameters to clinical outcome
and recanalization, as verified at duplex ultrasound scan-
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scoring system for evaluation of chronic venous disease.10
PATIENTS AND METHODS
Patients. All patients who had been referred to the
Division of Angiology, University Hospital Zurich, be-
tween Jan 1, 1994, and Sep 30, 2001, for evaluation of
suspected DVT were identified by review of patient charts.
All patients with DVT of the lower extremities, proved with
duplex ultrasound scanning or ascending phlebography,
were invited by telephone to participate in the study. Pa-
tients who consented were invited to return to the hospital
for a clinic visit, which consisted of a medical interview,
physical examination, color-coded duplex ultrasound scan-
ning of the veins, and determination of CRP, D-dimer, and
several rheologic variables.
After written informed consent was obtained, a precise
medical history was taken, with particular attention to
questions about the presence of thrombotic risk factors at
the onset of acute DVT, duration of anticoagulant therapy
after DVT, compression therapy, and eventual recurrent
thromboembolic events. In addition, particular attention
was paid to present comorbid conditions that may have
influenced inflammatory and rheologic parameters, such as
recent surgery or recent acute illness. Symptoms of CVI
were asked about according to a standardized question-
naire.
At clinical examination, signs of CVI were exactly re-
corded, and patients were classified according to the clinical
component (C) of the CEAP classification.3 Furthermore,
the Venous Clinical Severity Score (VCSS), as described by
Rutherford et al, was calculated.10 This score includes 9
clinical characteristics, and has been proposed by a Com-
mittee of the American Venous Forum as a quantitative
measure for clinical characterization of the severity of ve-
nous dysfunction. A thrombus score, as described by Porter
et al,3 was also calculated for each patient.
Methods. All patients underwent color-coded duplex
ultrasound scanning (Acuson 128XP) of the veins in the
affected leg.
For duplex ultrasound scanning, patients were placed
in a 15-degree reverse Trendelenburg position. The infe-
rior vena cava, iliac veins, common and superficial femoral
veins, popliteal veins, tibial-soleal veins, and greater and
minor saphenous veins were examined on the basis of
standard ultrasound criteria, including visibility of thrombi,
compressibility with external pressure, and presence of
spontaneous or augmented flow. Each segment was ac-
cordingly classified as patent, partially occluded, or com-
pletely occluded. Insufficient venous valves were identified
according to venous reflux during the Valsalva maneuver or
with distal manual compression. From these data the Ve-
nous Segmental Disease Score (VSDS), as described by
Rutherford et al,10 was calculated. This score is based on a
combination of anatomic and pathophysiologic compo-
nents. On the basis of appropriate venous imaging (duplex
ultrasound scanning or phlebography), 11 major venous
segments are graded according to the presence of reflux orobstruction. The segments are weighed with respect to
their relative importance when involved in reflux or ob-
struction, with a maximum score of 10.
Blood was drawn from the antecubital vein without
veno-occlusion, for determination of CRP concentration,
D-dimer, platelet count, white blood cell count, and rheo-
logic variables including fibrinogen, plasma viscosity, red
blood cell aggregation, whole blood viscosity, hematocrit,
and platelet aggregation.
Citrated plasma was used for the determination of plasma
fibrinogen, with the method of Clauss.11 Plasma viscosity was
determined in ethylenediamine tetraacetic acid (EDTA)
plasma with a viscometer of the capillary type at 25°C (Pro-
cesser viscosity system, PVS 1). Whole blood viscosity was
measured in EDTA plasma with a rotational viscometer (Con-
traves LS 30) at a medium shear rate (2.37/s) and a low shear
rate (0.695/s) at 37°C.12 Red cell aggregation in EDTA
blood was determined at a low shear rate (3/s) with a photo-
metric rheoscope (MA1-Aggregometer; Myrenne).13 EDTA
blood was centrifuged at 15,000g for 5 minutes for determi-
nation of microhematocrit levels. Platelet aggregation was
assessed by centrifuging (10 minutes, 1000g, room tempera-
ture) fresh citrated plasma (3.8%, 1:10) to obtain platelet-rich
plasma concentration. The remaining sample was recentri-
fuged (15 minutes, 3000g, room temperature) to obtain
platelet-poor plasma. Platelet-rich plasma was then adjusted
with platelet-poor plasma to achieve a final platelet count of
250 109/L. After stimulation with epinephrine (final con-
centration, 0.1 mmol/L), collagen (final concentration, 5
mg/L), and adenosine diphosphate (final concentration,
0.002 mol/l), maximal aggregation was measured with an
Table I. Patient characteristics
n %




Thrombosis risk factors at acute DVT event
Age 40 years 37 86.0
Malignancy 6 14.0
Immobilization 10 23.3
Estrogen therapy 8 18.6
Surgery 10 23.3
Cardiac disease 7 16.3
Prolonged travel (6 h) 4 9.3
Limb trauma 3 7.0
Family history 17 39.5
Previous DVT 6 14.0
Pregnancy 1 2.3
Known prothrombotic state 10 23.3
Obesity 5 11.6
Proximal/distal DVT (n) 21/22
Duration of anticoagulation therapy (mo)
(mean  SD)
6.2  5.8
Compression therapy 35 81
Duration (mo) (mean  SD) 9.8  10.3
Time since acute DVT (mo) (mean  SD) 28  19
Recurrent DVT since acute event 6 14
DVT, Deep venous thrombosis.
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photometrically as a change in light transmission over time.
Platelet aggregation studies were performed within 30 min-
utes after blood collection. All blood cell counts were assessed
with a semiautomated Sysmex K-1000 hematology analyzer
(Toa Medical Electronics).
Twenty-nine clinically healthy age-matched and sex-
matched subjects (12 men, 17 women; mean age, 52  8
years) served as control subjects. None had a history of
venous disease or any other serious disease. All were non-
smokers, and none were taking any medication. At clinical
examination none showed signs of venous disease or any
other disease, and results of routine laboratory studies were
normal.
Statistical analysis. All statistical analyses were per-
formed with Statview 5.0 software. Continuous variables
are reported as mean  SD, and categorical variables as
percentage. Two group comparisons for continuous vari-
Table II. Clinical findings in relation to duplex











n % n % n % n %
C0 4 3 75 1 25
C1 9 7 77 1 11 1 11
C2 8 6 75 1 12.5 1 12.5
C3 19 10 53 3 16 4 21 2 10
C4 2 1 50 1 50
C5 1 1 100





C-reactive protein (mg/L) 6.11 7.3 3  2.1 .01
D-Dimer (mg/L) 0.4  0.2 0.25  0.15 .05
Fibrinogen (mg/dL) 339 77 293  48 .01
Plasma viscosity (mPa.s) 1.6 0.2 1.58  0.9 NS
RCA low shear (AU) 47.7 10 40.2  10 .01
WBV low shear (mPa.s) 25.5 7.8 26.0 6.5 NS
WBV medium shear (mPa.s) 14.9 3.3 14.9 5.4 NS
Hematocrit (%) 36.7 3.4 37.4 2.6 NS
Platelet aggregation
ADP-induced (%) 46.1  25.1 48.4 24.9 NS
Epinephrine-induced (%) 63.6 19.4 62.3 16.9 NS
Collagen (%) 70.1 14.9 71.1 19.7 NS
Leukocytes (103/L) 6.56  2.8 5.26 1.2 .01
Platelets (103/L) 224.5  62.6229.3  62 NS
Values represent mean  SD.
RCA, Red cell aggregation; WBV, whole blood viscosity (ma); ADP,
adenosine diphosphate; platelet aggregation, collagen-induced; mPa.s, mil-
lipascal seconds; AU, arbitrary units; NS, not significant.ables were performed with the Mann-Whitney U test, and
for categorical variables with the 2 test.
Regression analysis was used to investigate the relation
between laboratory and rheologic variables, and venous
scores. Multivariate regression analysis was applied to ac-
count for the effect of possible confounders, including
laboratory and rheologic variables with imbalances (P .1)
between patients and control subjects, and clinical factors
such as age, total thrombus load, duration of compression
therapy, recurrence, recanalization, presence of comorbid
conditions. For the purpose of analysis, comorbid condi-
tions were grouped together and run as a variable. P  .05
was considered statistically significant.
RESULTS
Patients. Six hundred fourteen patients who had been
referred for evaluation of suspected DVT from Jan 1, 1994,
to Sep 30, 2001, were identified by chart review. In 181
patients (29%) DVT was proved at color-coded duplex
ultrasound scanning or phlebography. Of those, 170 (94%)
patients had DVT in lower extremities, and 11 (6%) pa-
tients had DVT in upper extremities. One hundred seven
patients (63%) refused to participate either because they
were unable or unwilling to return to the hospital, had
acute illnesses, or had undergone recent surgery, and were
excluded. Twenty patients (12%) had died meanwhile,
none because of venous thromboembolism. Finally, 43
(25%) patients with DVT in lower extremities were in-
cluded in the study.
Retrospective analysis of patient charts revealed that
patients who did not participate (n  127) and those who
eventually participated (n 43) did not differ with respect
to age (57.8  20 years vs 58  16 years; not significant
[NS]), sex (male-female ratio, 58:69 vs 15:28; NS), and
location of DVT (proximal-distal ratio, 68:59 vs 21:22;
NS). The mean number of risk factors was 2.5 1.8 versus
2.9 1.5 in patients who did not enter the study compared
with those who participated.
Characteristics of the 43 patients who eventually par-
ticipated are shown in Table I.
The mean number of risk factors per patient for devel-
opment of thrombosis at the time of acute DVT was 2.9
1.5. Thirty-four patients (79%) had permanent risk factors
(malignant tumor, inherited thrombophilia, advanced
age), and 9 patients (21%) had transient risk factors (travel
of long duration, immobilization). Twenty-one patients
(49%) had proximal DVT (thrombosis involving the pop-
liteal or more proximal veins), and 22 patients (51%) had
distal DVT. DVT occurred more often in the left leg (58%)
than in the right leg (42%).
All patients had initially been treated with therapeutic
doses of low molecular weight heparin (LMWH). Forty-
one patients subsequently were switched to coumarin; 2
patients continued LMWH because of contraindications to
coumarin therapy.
Compression therapy was classified as regular when
compression was applied at least 4 times per week during
the daytime.
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tients (14%) had recurrent DVT (18.7 14.4 months after
the first DVT event), in the ipsilateral leg in 3 patients.
Recurrence in these patients occurred at least 8 months
before performance of the present study.
Findings at clinical examination and duplex ultra-
sound scanning. Clinical findings, summarized as CEAP
class, were related to findings obtained at duplex ultra-
sound scanning, and are shown in Table II. At clinical
examination, most patients had CEAP class 1 to 3 disease,
and only 1 patient had CEAP class 5 disease.
Color-coded duplex ultrasound scans revealed com-
plete recanalization in 29 patients (67%), and obstruction
with or without reflux in 14 patients (33%). All patients
with complete recanalization had no or only mild CVI
(CEAP 0-3; Table II).
The mean value for all patients was 3.5 2.6 for VCSS,
and 0.7  1.6 for VSDS. The mean thrombus score was 1
 1.9 (data not shown).
Patients with proximal DVT had higher VSDS scores
(1.2 2.1 vs 0.3 0.6; P .05) and also higher thrombus
scores (1.6  2.4 vs 0.5  0.9; P  .05) compared with
patients with distal DVT. Furthermore, we found that
patients with severe CVI (class 4 or 5) had higher VCSS
scores (9.7 4.7 vs 3.0 1.8; P .001) and VSDS scores
(3.3 3.5 vs 0.6 1.3; P .005) compared with patients
with no or mild CVI (class 0-3).
CRP, D-dimer, and rheologic variables. Patients
had higher values for CRP, D-dimer, plasma fibrinogen, red
blood cell aggregation, and white blood cell counts than
did control subjects (Table III).
We found a significant correlation between CRP and
VCSS (r  0.42; P  .01), and red blood cell aggregation
and VCSS (r  0.30; P  .05; Figs 1 and 2).
There was a tendency for D-dimer to increase with
VCSS; however, significance was not reached (r  0.28;
P  .07; Fig 3.
For VSDS, we observed a trend to increase both with
VCSS (r  0.26; P  .09) and with CRP (r  0.26; P 
Fig 1. Correlation between C-reactive protein and Venous Clin-
ical Severity Score (VCSS)..09); no correlations were seen between VSDS and other
laboratory or rheologic variables (all NS).
We found no differences in laboratory and rheologic
variables between patient subgroups according to total
thrombus load at the index event (proximal or distal DVT),
recurrence and recanalization as verified at duplex ultra-
sound scanning (all NS).
Comorbid conditions present at follow-up are shown
in Table IV. CRP was not different in patients without
comorbid conditions and those with 1 or more comorbid
conditions: 5.2  7 mg/L (range, 2-37 mg/L) versus 8.0
 7.8 mg/L (range, 2-26 mg/L; P  .17).
Multivariate regression analysis showed that the relation
between CRP and VCSS was independent of other laboratory
and rheologic variables, and of age, total thrombus load,
duration of compression therapy, recurrence, recanalization,
and presence of comorbid conditions (P .02).
DISCUSSION
In the current work, we for the first time investigated
inflammatory parameters in conjunction with rheologic
variables in patients during the medium-term and long-
Fig 3. Correlation between D-dimer and Venous Clinical Sever-
ity Score (VCSS).
Fig 2. Correlation between red blood cell aggregation and Ve-
nous Clinical Severity Score (VCSS).
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eters with recently established clinical scores for assessment
of severity of venous dysfunction. VCSS has been estab-
lished as a quantifiable measure for severity of venous
dysfunction. We found that CRP, D-dimer, fibrinogen, red
blood cell aggregation, and leukocyte count were increased
in patients compared with control subjects. Furthermore,
both CRP and red blood cell aggregation were significantly
correlated with the clinical severity of CVI as assessed with
VCSS.
CRP is a marker of systemic inflammation, and has been
associated with increased risk for cardiovascular dis-
ease.14-16 CRP levels also predict future risk for develop-
ment of symptomatic peripheral artery disease.17 Both CRP
and D-dimer are inversely correlated with ankle-brachial
index in patients with a history of cardiac or cerebrovascular
disease,18 and are independently associated with altered
walking performance in patients with PAD.19 Mechanisms
that have been proposed to explain the effect of the inflam-
matory response, with CRP directly or indirectly contrib-
uting to the pro-inflammatory state, include impairment of
endothelial function20-22 and migration of leukocytes me-
diated by adhesion molecules.23 Recently, increased atten-
tion in clinical8 and experimental studies24 has been on not
only the involvement of inflammation in the pathogenesis
of arterial atherogenesis but also its association with venous
thrombogenesis. Studies in a mouse model of DVT re-
cently provided strong evidence for a causal relationship
between an inflammatory process and the development of
DVT.24 High circulating levels of pro-inflammatory adhe-
sion molecule P-selectin were associated with increased
thrombosis. In addition, leukocyte-derived microparticles,
which may be released after binding of P-selectin to its
receptor, were also associated with increased thrombus
formation.24 P-selectin expression on endothelial cells and
platelets may be increased when stimulated by cytokines,
which in turn are released from monocytes after CRP
stimulation. That the link between inflammation and
thrombosis might be a causal centerpiece in the pathogen-
esis of venous thrombosis is further supported by a recent
observational study in men that demonstrated increased
Table IV. Comorbid conditions present at follow-up
Comorbid condition n %
History of malignant disease; no active cancer 6 14
Cardiac disease: history of PCI; valvular heart
disease
7 16
Arterial hypertension 5 12




Cystic kidney disease 1 2
Thrombophilia: heterozygous factor V Leiden
mutation; increased thrombin-antithrombin
III complex; heparin co-factor II deficiency
5 12
PCI, Percutaneous coronary intervention.CRP levels in patients with acute DVT.8 We are the first to
show that this inflammatory response is not only associated
with the acute event, but may also be crucially involved in
development of CVI in the context of post-thrombotic
syndrome. Therefore, on the basis of our current data, we
postulate that inflammation and its pathophysiologic con-
sequences may well persist far beyond the acute event.
However, this may not yet necessarily imply causality. In
this context, that CRP levels were significantly associated
with CVI independent of ongoing chronic disease should
be emphasized. It remains unclear what determines clinical
outcome after the index DVT event, in particular, why the
inflammatory response apparently persists in some patients
in whom post-thrombotic CVI will develop. One possibil-
ity might be the concomitant occurrence of changes in
both inflammatory and rheologic status. Furthermore, al-
though not verified in our population, the presence or
persistence of other risk factors may contribute.
To the best of our knowledge, only 1 other study25
examined changes in coagulatory and pro-inflammatory
parameters in the setting of CVI. However, this study
included only consecutive patients with varicose veins in
whom CVI developed, whereas our study included patients
during the medium-term and long-term course after acute
DVT. However, in contrast to our study, no significant
increase in CRP or fibrinogen was found in those patients
with varicose veins and CVI.25 Therefore we may hypoth-
esize that the acute index event (DVT) must occur to
trigger the pathophysiologic events associated with post-
thrombotic CVI.
Although D-dimer level as a marker for ongoing fibrin
formation and degradation was significantly increased in
patients compared with control subjects, no significant
correlation could be established between D-dimer and
VCSS, even if there was a strong trend. This seems all the
more surprising because D-dimer induces the synthesis and
release of pro-inflammatory cytokines26 and may therefore
fit very well into the “inflammation-thrombosis hypothe-
sis” at the origin of DVT and post-thrombotic syndrome.
Mechanisms proposed for the relation between CRP and
CVI in the context of post-thrombotic syndrome may in
principle also apply for D-dimer. However, the size of the
patient group in our study may have been too small to
establish significance. Furthermore, during the long period
after the acute index event, other, non-DVT-related
sources of inflammatory stimulation might have occurred.
However, by taking an exact medical history, we strongly
believe we minimized, although not completely ruled out,
this possibility. The overall clinical classification of CVI in
the limbs was low, inasmuch as only 3 patients (7%) had
CEAP class 4 or 5 disease. Advanced grades of CVI are
more likely to entail an intrinsic inflammatory component.
Therefore an important possible confounder in this partic-
ular context seems unlikely to have relevantly contributed.
Despite a persistent inflammatory and pro-coagulant
state, as demonstrated by increased levels of CRP, fibrino-
gen, and leukocytes on the one hand, and D-dimer and red
blood cell aggregation on the other hand, duplex ultra-
JOURNAL OF VASCULAR SURGERY
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vealed complete recanalization. This may well be due to the
use of potent drugs (LMWH, coumarin) and regular use of
compression stockings.
Limitations of our study include the relatively small
number of patients, in particular the small number of
patients with severe venous insufficiency. Furthermore, al-
though significance could be statistically documented, the
correlations are rather weak, which might, at least in part,
be due to the small number of patients. And last, definitive
proof of causality and a cause-effect relationship cannot be
established.
Recently the VCSS proposed by the American Venous
Forum has been validated against an objective test (duplex
ultrasound scanning).27 In our study it also proved to be a
reliable and useful score for assessing venous outcome.
That some of the parameters, CRP and red blood cell
aggregation, were particularly well correlated with the clin-
ical assessment of venous outcome, as evaluated by the
recently established VCSS, may make them attractive mark-
ers for follow-up of patients in the future.
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